PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Wille, K.* ; Dumke, M.* ; Wilsdorf, N.* ; Sadjadian, P.* ; Schneider, A.* ; Jender-Bartling, S.* ; Kolatzki, V.* ; Horstmann, A.* ; Meixner, R. ; Jiménez-Muñoz, M. ; Fuchs, C. ; Tischler, H.J.* ; Griesshammer, M.*

Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia.

Eur. J. Haematol., DOI: 10.1111/ejh.14302 (2024)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
INTRODUCTION: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes. PATIENTS AND METHODS: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.0 months compared standard salvage chemotherapy (FLAG-Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG-Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy. RESULTS: Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log-rank-test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group. CONCLUSIONS: The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy.
Impact Factor
Scopus SNIP
Altmetric
2.300
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Flavida ; Acute Myelocytic Leukemia (aml) Leukemia ; Refractory ; Relapsed ; Venetoclax; Recommendations; Chemotherapy
Language english
Publication Year 2024
HGF-reported in Year 2024
ISSN (print) / ISBN 0036-553X
e-ISSN 1600-0609
Journal European Journal of Haematology
Publisher Wiley
Publishing Place 111 River St, Hoboken 07030-5774, Nj Usa
Reviewing status Peer reviewed
Institute(s) CF Statistical Consulting (CF-STATCON)
POF-Topic(s) 30505 - New Technologies for Biomedical Discoveries
Research field(s) Enabling and Novel Technologies
PSP Element(s) A-632200-001
DOI 10.1111/ejh.14302
WOS ID 001309263100001
Scopus ID 85203465843
PubMed ID 39252514
Erfassungsdatum 2024-10-15
[➜Report correction]